The Secret Sauce To BenevolentAI’s Ongoing Success

In a crowded AI-driven drug development sector, BenevolentAI stands out with its broad pipeline of drug candidates, deep pockets, and a growing partnership with AstraZeneca. Ivan Griffin, company co-founder and chief operating officer spoke with In Vivo about the formula behind the company’s successes.    

Ivan Griffin
BenevolentAI's Ivan Griffin • Source: BenevalentAI

While over 270 companies are doing artificial intelligence-driven drug development, many potential partners and investors are holding out for the first fruits of AI-based approaches. However, BenevolentAI Limited is being championed not only by investors, but by large pharma companies that have benefited from their work.

“There’s something happening in our sector,” said Ivan Griffin, co-founder and chief operating officer of the London, UK-headquartered biotech. “Investment...

More from C-Suite Speaks

More from Leadership